FOXO4-DRI (Proxofim) FOXO4-DRI (Proxofim) is a synthetic peptide studied for its ability to target senescent cells by disrupting FOXO4p53 interactions
for making drug claims about the following dietary supplements: Candicid Forte, Inflamma-bLOX, Lipitrol, Mucosagen, Prostatrol Forte, Resvoxitrol, Paracid Forte, VascuPak HTN and Lithium Orotate
By activating GIP receptors, tirzepatide enhances insulin secretion in a glucose-dependent manner, meaning insulin release occurs primarily when blood glucose levels are elevated, thereby reducing the risk of hypoglycemia
Common symptoms include: Nausea or vomiting after meals Abdominal discomfort Diarrhea or urgency to pass stools Lightheadedness or fainting Rapid pulse Low blood sugar symptoms in late dumping syndrome If symptoms interfere with daily activities or nutrition, medical evaluation is important
The Australian Therapeutic Goods Administration (TGA) has issued safety alerts after laboratory testing confirmed that some imported weight loss products marketed as GLP-1 therapies are counterfeit and contain no GLP-1 receptor agonist at all
Immune Resilience Supports balanced day-to-day wellness
